Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (1119)	5/14/2003 12:46:22 AM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 1834

Endocrinology Vol. 144, No. 6 2396-2403 Copyright © 2003 by The Endocrine Society Role of Corticotropin-Releasing Factor Receptors Type 1 and 2 in Modulating the Rat Adrenocorticotropin Response to Stressors Catherine L. Rivier, Dimitri E. Grigoriadis and Jean E. Rivier The Clayton Foundation Laboratories for Peptide Biology, The Salk Institute, La Jolla, California 92037; and Neurocrine Biosciences Inc., San Diego, California 92121 Address all correspondence and requests for reprints to: Catherine Rivier, Ph.D., The Salk Institute, 10010 North Torrey Pines Road, La Jolla, California 92037. E-mail: crivier@salk.edu. We investigated the contribution of corticotropin-releasing factor (CRF) receptors types 1 and 2 (CRF1 and CRF2) in mediating the ACTH response to shock, alcohol injection, or endotoxemia in the rat. Peptidic (Astressin B and Astressin2-B) and nonpeptidic (NBI 30775) CRF antagonists were injected iv before the stressors at doses previously shown to be effective in blocking the corresponding receptors. Because NBI 30775, which specifically blocks CRF1, penetrates the brain following systemic injection, we also compared its effect with that of Astressin B, which primarily, though not exclusively, targets CRF1 but does not cross the blood-brain barrier. Shocks, alcohol (4.5 g/kg, intragastrically) or lipopolysaccharide (LPS, 1 µg/kg, iv) all significantly released ACTH. Astressin B or NBI 30775 markedly decreased the effect of shocks or alcohol and also interfered, though less significantly so, with the influence of LPS. In contrast, specific blockade of CRF2 with Astressin2-B, although not significantly altering the overall ACTH response to shocks, alcohol, or LPS, slightly enhanced ACTH levels during the early phase of some of these responses. Interestingly, combined administration of NBI 30775 and Astressin2-B decreased ACTH levels more than NBI 30775 alone, although this difference did not reach statistical significance. Finally, blockade of CRF1 and/or CRF2 augmented LPS- induced TNF- and IL-6 release. Collectively, there results confirm the critical role played by CRF1 in mediating the ACTH response to shocks, alcohol and LPS, whereas the influence of CRF2 remains subtle. Finally, we showed that peripheral endogenous CRF restrains the ability of LPS to release cytokines.